FDA Brief

Warning letters Drugs

FDA warning letter to

Wisconsin Pharmacal Company, LLC

High riskIssued Aug 22, 2025Posted Sep 2, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Wisconsin Pharmacal over OTC drug manufacturing violations, including released rejected product and S. aureus contamination.

What happened

FDA inspected Wisconsin Pharmacal’s drug manufacturing facility in Jackson, WI, from March 3 to 7, 2025. The agency found that the quality unit allowed distribution of rejected OTC drug units, that S. aureus contamination in batches was not thoroughly investigated before release based on retests, and that laboratory computer systems lacked controls and audit trail review.

What FDA found

  1. The quality unit lacked adequate oversight and allowed distribution of rejected OTC drug units, including about half of a rejected batch.

    21 CFR 211.22
  2. The firm failed to thoroughly investigate S. aureus contamination and released batches based on passing retests without determining the root cause.

    21 CFR 211.192
  3. The firm lacked controls over laboratory computer systems, including administrative privileges and audit trail review.

    21 CFR 211.68(b)

What FDA wants

FDA tells the company to respond in writing within 15 working days with corrective actions and comprehensive assessments and remediation plans for its quality unit, investigations and microbial contamination, and computer system controls, or state why it cannot complete the actions and give a schedule.

Who should pay attention

  • companies that buy OTC drug products from this manufacturer
  • contract manufacturers with similar quality-unit oversight
  • quality and lab managers responsible for microbial testing and data integrity

This is a summary. Read the original letter on fda.gov.

Wisconsin Pharmacal Company, LLC's FDA history

Recalls in the last 12 months

May 27 Class I Wisconsin Pharmacal Company
Drug
MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%), NET WT 6 oz (170 g), Manufactured by: Pharmacal 1 Pharmacal Way, P.O. Box 198, Jackson, WI 53037.
Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.

Full company page

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk